1			
2 3 4	1	Title: Save the COVID-19 point of care nucleic acid test swab after testing to identify variants of	of
5 6	2	concern	
7 8 9	3	Running Head: COVID-19 ID NOW residual swab for variant testing	
10 11	4	Authors: Byron M. Berenger <sup>1,2</sup> , William Stokes <sup>1,3,4</sup> , Leeann Turnbull <sup>1</sup> , Kanti Pabbaraju <sup>1</sup> , Nathan	
12 13 14	5	Zelyas <sup>1,3</sup> , Allison A. Venner <sup>2,5</sup> , Graham A. Tipples <sup>1,6,7</sup>	
15 16	6	<sup>1</sup> Alberta Public Health Laboratory, Alberta Precision Laboratories, AB, Canada	
17 18	7	<sup>2</sup> Department of Pathology and Laboratory Medicine, University of Calgary, Calgary, AB, Canada	E
19 20 21	8	<sup>3</sup> Department of Laboratory Medicine and Pathology, University of Alberta, AB, Canada	
22 23	9	<sup>4</sup> Division of Infectious Diseases, Department of Medicine, University of Alberta, Edmonton, AB	,
24 25 26	10	Canada	
20 27 28	11	<sup>5</sup> Point of Care Testing, Alberta Precision Laboratories, AB, Canada	
29	12	<sup>6</sup> Department of Medical Microbiology and Immunity, Faculty of Medicine, University of Alberta,	
30 31 32	13	Edmonton, AB, Canada	
33 34	14	<sup>7</sup> Li Ka Shing Institute of Virology, University of Alberta, Edmonton, AB, Canada	
35 36 37	15	Corresponding Author:	
38 39	16	Byron M. Berenger	
40 41	17	3300 Hospital Drive NW Calgary, AB T2N 4W4	
42 43 44	18	Phone: 587-779-5573 E-mail: byron.berenger@ucalgary.ca	
45 46	19	Keywords: point of care testing, POCT, SARS-CoV-2, COVID-19, variants of concern, ID NOW,	
47 48	20	swab.	
49 50 51	21	Nonstandard Abbreviations: SARS-CoV-2, Severe acute respiratory syndrome-coronavirus-2;	
52	22	rRT-PCR, reverse transcriptase real-time polymerase chain reaction; COVID-19, coronavirus	
53 54 55	23	infectious disease-2019; VoC, variants of concern; POCT, point of care testing, NPS,	
56 57 58 59		© American Association for Clinical Chemistry 2021. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com	1

nasopharyngeal swab; rSwab, residual ID NOW swab; NPS-dxPCR, diagnostic SARS-CoV-2 PCR
 done on NPS; rSwab-dxPCR, diagnostic SARS-CoV-2 PCR done on NPS

 Point of care testing (POCT) for severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2), such as the Abbott ID NOW<sup>TM</sup> isothermal nucleic acid test, improve the turnaround time of laboratory results and make testing more widely available. Since the beginning of the coronavirus infectious disease-2019 (COVID-19) pandemic, typing of SARS-CoV-2 has been an important component to the pandemic response. With the emergence of variants of concern (VoC), typing has become a critical tool utilized by public health and infection prevention and control for case management. Although POCT has many benefits, one downside is that unless a second swab is collected, no sample is available to the laboratory for further analysis. Using a prospective study design, we determined if the ID NOW swab could be used for confirmatory PCR or variant testing after mixing in the sample receiver to perform the POCT. People with symptoms of COVID-19 or those considered as asymptomatic close contacts to a confirmed case as per Alberta Health guidelines (1) were eligible for POCT ID NOW testing at community collection and test (assessment) centres in the province of Alberta, Canada. Two swabs were collected by health care workers: a throat swab for ID NOW and a nasopharyngeal swab (NPS) in universal transport media (UTM; GDL Korea Co. Ltd, Anyang, South Korea) for confirmation of negative results or VoC typing of positive results. As per manufacturer instructions, the ID NOW swab was mixed in the sample receiver buffer on the ID NOW instrument and then discarded after testing. When collecting swabs and testing on the ID NOW,

 contact and droplet precautions (gown, gloves, and eye/face mask) were used. For this study,

Page 3 of 6

1 2		
3 4	46	after POCT ID NOW testing, the residual throat swab (rSwab) was saved in a sterile container or
5 6 7	47	original packaging and, if positive, the swab was added to a tube with 2 mL of UTM. The rSwab
8 9	48	and NPS were shipped to the laboratory at room temperature and refrigerated upon arrival
10 11	49	until testing within 48 h of receipt. SARS-CoV-2 diagnostic PCR on the rSwab and NPS SARS-CoV-
12 13 14	50	2 PCR (rSwab-dxPCR; NPS-dxPCR) was initially tested on the Cobas 6800 (Roche, Basel,
15 16	51	Switzerland) or using the Alberta Public Health Lab (ProvLab) E gene PCR (2). If SARS-CoV-2
17 18 19	52	dxPCR positive, samples were tested with a ProvLab B.1.1.7 (Alpha) VoC PCR (vPCR) (3). The
20 21	53	vPCR detected the routine diagnostic E gene target and two S gene mutations (N501Y and the
22 23 24	54	69/70 deletion). Samples were considered positive for the Alpha VoC if positive for both the
24 25 26	55	N501Y mutation and 69/70 deletion, wild type if the 69/70 deletion alone was positive or both
27 28	56	targets were negative, or presumptive variant of concern if the N501Y target alone was
29 30 31	57	positive. Samples negative for the E gene target or with a cycle threshold (Ct) >35 were deemed
32 33	58	"unresolved". Next generation sequencing was only performed on presumptive VoC (N501Y
34 35 36	59	positive and no 69/70 deletion) and other select samples if the Ct was <32 (due to high
37 38	60	likelihood of next generation sequencing failure at low viral loads). Technologists performing
39 40 41	61	PCR testing were unaware of the ID NOW results.
42 43	62	Swabs were collected from April 19-29, 2021. Compared to the ID NOW result, the positive
44 45		
46 47	63	agreement for rSwab-PCR was 101/113 (89.4%; 95% CI 82.4-93.8) and for NPS-dxPCR, 98.2%
48 49	64	(95% CI 93.7-99.7) (Table 1). The difference between rSwab-dxPCR and NPS-dxPCR was
50 51 52	65	statistically significant (p=0.0104, Fisher's exact). The positive agreement of rSwab-dxPCR
52 53 54	66	compared to NPS-dxPCR was 90.1 % (95% CI 83.1-94.3, p=0.008).
55 56		
57 58		2

Manuscripts submitted to Clinical Chemistry

2	
3	
4	
5	
6	
7	
8	
9	
10	
11	
12	
13	
14	
15	
16	
17	
18	
19	
20	
21	
22	
23	
24	
25	
26	
27	
28	
29	
30	
31	
32	
33	
34	
35	
36	
37	
38	
39	
40	
41	
42	
43	
44	
45	
46	
47	
48	
49	
50	
51	
52	
53	
55 54	
55	
56	
57	
58	
59	
60	

60

67	Fifteen rSwab and NPS samples were not tested by vPCR due to laboratory error. Excluding
68	these 15 samples (total 98 paired samples), 79.6% (78/98) rSwab gave a vPCR result of positive
69	or negative for the Alpha VoC compared to 95.9% (94/98) from the NPS (Table 2). Other
70	samples that did not give a result were either not eligible for vPCR because they were negative
71	by initial PCR screen or unresolved by the vPCR.
72	Only 83.2% (94/113) of the rSwabs would have been whole genome sequencing eligible (Ct <32)
73	compared to 93.8% of the NPS (106/113). The median Ct for the rSwab was significantly higher
74	than the paired NPS at 27.0 (IQR 24.1-30.4) vs 21.8 (IQR 17.7-26.2), respectively (p<0.0001,
75	Wilcoxon-signed rank). This included negatives as zero and excluded indeterminates or
76	positives without a Ct value (n=108). Linear regression yielded a correlation coefficient (r <sup>2</sup> ) of
77	0.0746.
78	Using the rSwab is not as sensitive as collecting second NPS and reduces the number of samples
79	with variant result. It does, however, offer an option when a second swab cannot be obtained
80	and a 20% reduction in the ability to identify variants in positive cases is acceptable.
81	
82	
83	Acknowledgments: We thank Alberta Health Services and Alberta Precision Laboratory staff for the
84	collection and testing of samples.
85	
00	
86	

4       Author Contributions: All authors confirmed they have contributed to the intellectual content of this         8       paper and have met the following 4 requirements: (a) significant contributions to the conception and         9       design, acquisition of data, or analysis and interpretation of data; (b) drafting or revising the article for         9       intellectual content; (c) final approval of the published article and (d) agreement to be accuratible for         9       authors' Disclosures or Potential Conflicts of Interest: Upon manuscript submission, all authors         9       completed the author disclosure form. Disclosures and/or potential conflicts of interest:         9       Stock Ownership: None declared.         9       Stock Ownership: None declared.         10       Honoraria: None declared.         10       Honoraria: None declared.         10       Honoraria: None declared.         10       Research Funding: This work was funded using internal operating funds of Alberta Precision         110       Laboratories and Albera Health Services. Test kits and instruments were paid for by the Public Health         10       References:         101       References:         102       Laboratories and Albera Health Services. Test kits and instruments were paid for by the Public Health Disease         108       Nanagement Guideline. March 24, 2021. Accressed online May 31, 2021:	1		
<ul> <li>paper and have met the following a requirements: (a) significant contributions to the conception and design, acquisition of data, or analysis and interpretation of data; (b) drafting or revising the article for</li> <li>intellectual content; (c) final approach of the published orticle; and (d) agreement to be accountable for</li> <li>all aspects of the article thus ensuring that questions related to the accuracy or integrity of any part of the article are appropriately investigated and resolved.</li> <li>Authors' Disclosures or Potential Conflicts of Interest: Upon manuscript submission, all authors completed the author disclosure form. Disclosures and/or potential conflicts of interest:</li> <li>Employment or Leadership: None declared.</li> <li>Consultant or Advisory Role: None declared.</li> <li>Honorrai: None declared.</li> <li>Honorrai: None declared.</li> <li>Honorrai: None declared.</li> <li>Agency of Canada.</li> <li>Expert Testimony: None declared.</li> <li>Patents: None declared.</li> <li>Patents: None declared.</li> <li>Patents: None declared.</li> <li>References:</li> <li>In Ministry of Health, Government of Alberta. Coronavirus, Novel Public Health Disease</li> <li>Management Guideline. March 24, 2021. Accessed online May 31, 2021:</li> <li>https://open.alberta.ca/publications/coronavirus-covid-19</li> <li>Pabaraju K, Wong AA, Douesnard M, Ma R, Gill K, Dieu P, Fonseca K. Development and</li> <li>validation of RT-PCR assays for testing for SARS-CoV-2. Official Journal of the Association</li> <li>of Medical Microbiology and Infectious Disease Canada 2021;6:116-22.</li> <li>Zelyas N, Pabbaraju K, Croxen MA, Lynch T, Buss E, Murphy SA. 2021. Precision response</li> <li>to the rise of the SARS-CoV-2 B.1.1.7 variant of concern by combining novel PCR assays</li> <li>and genome sequencing for rapid variant detection and surveillance. Microbiol Spectr</li> <li>2021;9:e00315-21.</li> </ul>			
<ul> <li>piper tub nucle new polyment of analysis and interpretation of data; (b) dright go revising the article for intellectual content; (c) final approval of the published article; and (d) garement to be accountable for intellectual content; (c) final approval of the published article; and (d) garement to be accountable for d aspects of the article thus ensuing that questions related to the accuracy or integrity of any part of the article are appropriately investigated and resolved.</li> <li>Authors' Disclosures or Potential Conflicts of Interest: Upon manuscript submission, all authors completed the author disclosure form. Disclosures and/or potential conflicts of interest:</li> <li>Employment or Leadership: None declared.</li> <li>Stock Ownership: None declared.</li> <li>Besearch Funding: This work was funded using internal operating funds of Alberta Precision Laboratories and Alberta Health Services. Test kits and instruments were paid for by the Public Health Agency of Canada.</li> <li>Patents: None declared.</li> <li>Disclosures of the disclosures of the disclosure of the disclosu</li></ul>			
<ul> <li>design, bickestolo of adda, or analysis and interpretation of adda, or analysis and addition of addition</li></ul>			
all aspects of the article thus ensuring that questions related to the accuracy or integrity of any part of         the article are appropriately investigated and resolved.         authors' Disclosures or Potential Conflicts of Interest: Upon manuscript submission, all authors         completed the author disclosure form. Disclosures and/or potential conflicts of interest:         completed the author disclosure form. Disclosures and/or potential conflicts of interest:         generation         consultant or Advisory Role: None declared.         Stock Ownership: None declared.         Honoraria: None declared.         Research Funding: This work was funded using internal operating funds of Alberta Precision         Laboratories and Alberta Health Services. Test kits and instruments were paid for by the Public Health         agency of Canada.         200         Patents: None declared.         201         202         203         204         204         205         206         206         207         208         208         209         2010         2011         2012         2013         2014         2015         2016         2016     <			
92       the article are appropriately investigated and resolved.         93       Authors' Disclosures or Potential Conflicts of Interest: Upon manuscript submission, all authors         94       Authors' Disclosures or Potential Conflicts of Interest: Upon manuscript submission, all authors         95       completed the author disclosure form. Disclosures and/or potential conflicts of interest:         96       Employment or Leadership: None declared.         97       Employment or Advisory Role: None declared.         98       Stock Ownership: None declared.         99       Stock Ownership: None declared.         90       Honoraria: None declared.         91       Laboratories and Alberta Health Services. Test kits and instruments were paid for by the Public Health         91       Agency of Canada.         92       Patents: None declared.         93       Patents: None declared.         94       Patents: None declared.         95       Patents: None declared.         96       Management Guideline. March 24, 2021. Accessed online May 31, 2021:         97       https://open.alberta.ca/publications/coronavirus-covid-19         98       1       Pabbaraju K, Wong AA, Douesnard M, Ma R, Gill K, Dieu P, Fonseca K. Development and         99       validation of RT-PCR assays for testing for SARS-CoV-2. Official Journal of the Association			
93       Authors' Disclosures or Potential Conflicts of Interest: Upon manuscript submission, all authors completed the author disclosure form. Disclosures and/or potential conflicts of interest:         94       Employment or Leadership: None declared.         95       Consultant or Advisory Role: None declared.         96       Stock Ownership: None declared.         97       Employment or Leadership: None declared.         98       Stock Ownership: None declared.         99       Research Funding: This work was funded using internal operating funds of Alberta Precision         91       Research Funding: This work was funded using internal operating funds of Alberta Precision         91       Research Funding: This work was funded using internal operating funds of Alberta Precision         92       Laboratories and Alberta Health Services. Test kits and instruments were paid for by the Public Health         93       Authors' Of Ganda.       Expert Testimony: None declared.         94       Patents: None declared.       106         95       Patents: None declared.       107         96       Management Guideline. March 24, 2021. Accessed online May 31, 2021:       11         97       https://open.alberta.ca/publications/coronavirus-covid-19       11         98       1       Pabbaraju K, Wong AA, Douesnard M, Ma R, Gill K, Dieu P, Fonseca K. Development and         91			
11       94       Authors' Disclosures or Potential Conflicts of Interest: Upon manuscript submission, all authors         13       95       completed the author disclosure form. Disclosures and/or potential conflicts of interest:         14       97       Employment or Leadership: None declared.         15       98       Consultant or Advisory Role: None declared.         16       99       Stock Ownership: None declared.         100       Honoraria: None declared.       100         101       Research Funding: This work was funded using internal operating funds of Alberta Precision         112       Laboratories and Alberta Health Services. Test kits and instruments were paid for by the Public Health         102       Laboratories and Alberta Health Services. Test kits and instruments were paid for by the Public Health         103       Agency of Canada.       Expert Testimony: None declared.         104       Expert Testimony: None declared.       Patents: None declared.         105       Patents: None declared.       106         106       Interest:       107         107       References:       108         108       1. Ministry of Health, Government of Alberta. Coronavirus, Novel Public Health Disease         109       Management Guideline. March 24, 2021. Accessed online May 31, 2021:         110       https://open.alberta.			the article are appropriately investigated and resolved.
<ul> <li>completed the author disclosure form. Disclosures and/or potential conflicts of interest:</li> <li>Employment or Leadership: None declared.</li> <li>Consultant or Advisory Role: None declared.</li> <li>Stock Ownership: None declared.</li> <li>Honoraris: None declared.</li> <li>Research Funding: This work was funded using internal operating funds of Alberta Precision</li> <li>Laboratories and Alberta Health Services. Test kits and instruments were paid for by the Public Health Agency of Canada.</li> <li>Expert Testimony: None declared.</li> <li>Patents: None declared.</li> <li>Pa</li></ul>			Authors/ Disclosures on Detection Conflicts of Interests // and menoristics in the interest of the second
<ul> <li><sup>13</sup><sup>15</sup><sup>15</sup><sup>15</sup><sup>15</sup><sup>15</sup><sup>15</sup><sup>15</sup><sup>15</sup><sup>15</sup><sup>15</sup></li></ul>			
<ul> <li>Employment or Leadership: None declared.</li> <li>Consultant or Advisory Role: None declared.</li> <li>Stock Ownership: None declared.</li> <li>Honoraris: None declared.</li> <li>Research Funding: This work was funded using internal operating funds of Alberta Precision</li> <li>Laboratories and Alberta Health Services. Test kits and instruments were paid for by the Public Health</li> <li>Agency of Canada.</li> <li>Expert Testimony: None declared.</li> <li>Patents: None declared.</li> <li>Ministry of Health, Government of Alberta. Coronavirus, Novel Public Health Disease</li> <li>Management Guideline. March 24, 2021. Accessed online May 31, 2021:</li> <li>https://open.alberta.ca/publications/coronavirus-covid-19</li> <li>Pabbaraju K, Wong AA, Douesnard M, Ma R, Gill K, Dieu P, Fonseca K. Development and</li> <li>validation of RT-PCR assays for testing for SARS-CoV-2. Official Journal of the Association</li> <li>of Medical Microbiology and Infectious Disease Canada 2021;6:116-22.</li> <li>Zelyas N, Pabbaraju K, Croxen MA, Lynch T, Buss E, Murphy SA. 2021. Precision response</li> <li>to the rise of the SARS-CoV-2 B.1.1.7 variant of concern by combining novel PCR assays</li> <li>and genome sequencing for rapid variant detection and surveillance. Microbiol Spectr</li> <li>2021;9:e00315-21.</li> </ul>			completed the duthor disclosure form. Disclosures and/or potential conflicts of interest:
<ul> <li>Consultant or Advisory Role: None declared.</li> <li>Stock Ownership: None declared.</li> <li>Honoraria: None declared.</li> <li>Research Funding: This work was funded using internal operating funds of Alberta Precision</li> <li>Laboratories and Alberta Health Services. Test kits and instruments were paid for by the Public Health</li> <li>Agency of Canada.</li> <li>Expert Testimony: None declared.</li> <li>Patents: None declared.</li> <li>None declared.</li> <li>Ninistry of Health, Government of Alberta. Coronavirus, Novel Public Health Disease</li> <li>Management Guideline. March 24, 2021. Accessed online May 31, 2021:</li> <li>https://open.alberta.ca/publications/coronavirus-covid-19</li> <li>Pabbaraju K, Wong AA, Douesnard M, Ma R, Gill K, Dieu P, Fonseca K. Development and</li> <li>validation of RT-PCR assays for testing for SARS-CoV-2. Official Journal of the Association</li> <li>of Medical Microbiology and Infectious Disease Canada 2021;6:116-22.</li> <li>Zelyas N, Pabbaraju K, Croxen MA, Lynch T, Buss E, Murphy SA. 2021. Precision response</li> <li>to the rise of the SARS-CoV-2 B.1.1.7 variant of concern by combining novel PCR assays</li> <li>and genome sequencing for rapid variant detection and surveillance. Microbiol Spectr</li> <li>2021;9:e00315-21.</li> </ul>			Fuer la versent en la sola de la so
<ul> <li>Stock Ownership: None declared.</li> <li>Honoraria: None declared.</li> <li>Research Funding: This work was funded using internal operating funds of Alberta Precision</li> <li>Laboratories and Alberta Health Services. Test kits and instruments were paid for by the Public Health</li> <li>Agency of Canada.</li> <li>Expert Testimony: None declared.</li> <li>Patents: None declared.</li> <li>Patents: None declared.</li> <li>References:</li> <li>Ministry of Health, Government of Alberta. Coronavirus, Novel Public Health Disease</li> <li>Management Guideline. March 24, 2021. Accessed online May 31, 2021:</li> <li>https://open.alberta.ca/publications/coronavirus-covid-19</li> <li>Pabbaraju K, Wong AA, Douesnard M, Ma R, Gill K, Dieu P, Fonseca K. Development and</li> <li>validation of RT-PCR assays for testing for SARS-CoV-2. Official Journal of the Association</li> <li>of Medical Microbiology and Infectious Disease Canada 2021;6:116-22.</li> <li>Let validation of RT-PCR assays for rapid variant detection and surveillance. Microbiol Spectr</li> <li>2021;9:e00315-21.</li> </ul>	15		
100       Honoraria: None declared.         101       Research Funding: This work was funded using internal operating funds of Alberta Precision         102       Laboratories and Alberta Health Services. Test kits and instruments were paid for by the Public Health         102       Agency of Canada.         103       Expert Testimony: None declared.         104       Expert Testimony: None declared.         105       Patents: None declared.         106       .         107       References:         108       1. Ministry of Health, Government of Alberta. Coronavirus, Novel Public Health Disease         108       1. Ministry of Health, Government of Alberta. Coronavirus, Novel Public Health Disease         109       Management Guideline. March 24, 2021. Accessed online May 31, 2021:         110       https://open.alberta.ca/publications/coronavirus-covid-19         121       .         122       Pabbaraju K, Wong AA, Douesnard M, Ma R, Gill K, Dieu P, Fonseca K. Development and         112       validation of RT-PCR assays for testing for SARS-CoV-2. Official Journal of the Association         123       of Medical Microbiology and Infectious Disease Canada 2021;6:116-22.         124       3. Zelyas N, Pabbaraju K, Croxen MA, Lynch T, Buss E, Murphy SA. 2021. Precision response         125       to the rise of the SARS-CoV-2 B.1.1.7 variant of concern by com			•
101       Research Funding: This work was funded using internal operating funds of Alberta Precision         102       Laboratories and Alberta Health Services. Test kits and instruments were paid for by the Public Health         103       Agency of Canada.         104       Expert Testimony: None declared.         105       Patents: None declared.         106       Patents: None declared.         107       References:         108       1. Ministry of Health, Government of Alberta. Coronavirus, Novel Public Health Disease         109       Management Guideline. March 24, 2021. Accessed online May 31, 2021:         110       https://open.alberta.ca/publications/coronavirus-covid-19         111       2. Pabbaraju K, Wong AA, Douesnard M, Ma R, Gill K, Dieu P, Fonseca K. Development and         118       validation of RT-PCR assays for testing for SARS-CoV-2. Official Journal of the Association         113       of Medical Microbiology and Infectious Disease Canada 2021;6:116-22.         114       3. Zelyas N, Pabbaraju K, Croxen MA, Lynch T, Buss E, Murphy SA. 2021. Precision response         115       to the rise of the SARS-CoV-2 B.1.1.7 variant of concern by combining novel PCR assays         116       and genome sequencing for rapid variant detection and surveillance. Microbiol Spectr         117       2021;9:e00315-21.         118       2021;9:e00315-21. <td></td> <td></td> <td>•</td>			•
101       Laboratoria and Alberta Health Services. Test kits and instruments were paid for by the Public Health         111       Agency of Canada.         112       Expert Testimony: None declared.         116       Patents: None declared.         117       Patents: None declared.         118       Image: Instance of the second se			
102       Laboratories and Alberta Health Services. Test kits and instruments were paid for by the Public Health         103       Agency of Canada.         104       Expert Testimony: None declared.         105       Patents: None declared.         106       107         108       1. Ministry of Health, Government of Alberta. Coronavirus, Novel Public Health Disease         109       Management Guideline. March 24, 2021. Accessed online May 31, 2021:         110       https://open.alberta.ca/publications/coronavirus-covid-19         111       2. Pabbaraju K, Wong AA, Douesnard M, Ma R, Gill K, Dieu P, Fonseca K. Development and         112       validation of RT-PCR assays for testing for SARS-CoV-2. Official Journal of the Association         113       of Medical Microbiology and Infectious Disease Canada 2021;6:116-22.         114       3. Zelyas N, Pabbaraju K, Croxen MA, Lynch T, Buss E, Murphy SA. 2021. Precision response         115       to the rise of the SARS-CoV-2 B.1.1.7 variant of concern by combining novel PCR assays         116       and genome sequencing for rapid variant detection and surveillance. Microbiol Spectr         117       2021;9:e00315-21.         118       2021;9:e00315-21.			
23       104       Expert Testimony: None declared.         24       105       Patents: None declared.         26       106         27       106         28       107         29       107         8       1. Ministry of Health, Government of Alberta. Coronavirus, Novel Public Health Disease         31       108         32       109         34       109         35       Management Guideline. March 24, 2021. Accessed online May 31, 2021:         36       https://open.alberta.ca/publications/coronavirus-covid-19         37       110       https://open.alberta.ca/publications/coronavirus-covid-19         38       111       2. Pabbaraju K, Wong AA, Douesnard M, Ma R, Gill K, Dieu P, Fonseca K. Development and         41       112       validation of RT-PCR assays for testing for SARS-CoV-2. Official Journal of the Association         42       113       of Medical Microbiology and Infectious Disease Canada 2021;6:116-22.         44       113       zelyas N, Pabbaraju K, Croxen MA, Lynch T, Buss E, Murphy SA. 2021. Precision response         45       114       3. Zelyas N, Pabbaraju K, Croxen MA, Lynch T, Buss E, Murphy SA. 2021. Precision response         46       115       to the rise of the SARS-CoV-2 B.1.1.7 variant of concern by combining novel PCR assays		102	Laboratories and Alberta Health Services. Test kits and instruments were paid for by the Public Health
24       105       Patents: None declared.         25       106         27       107         28       107         29       108         108       1. Ministry of Health, Government of Alberta. Coronavirus, Novel Public Health Disease         30       Management Guideline. March 24, 2021. Accessed online May 31, 2021:         36       https://open.alberta.ca/publications/coronavirus-covid-19         37       110       https://open.alberta.ca/publications/coronavirus-covid-19         38       112       validation of RT-PCR assays for testing for SARS-CoV-2. Official Journal of the Association         41       112       validation of RT-PCR assays for testing for SARS-CoV-2. Official Journal of the Association         42       113       of Medical Microbiology and Infectious Disease Canada 2021;6:116-22.         44       13       of Medical Microbiology and Infectious Disease Canada 2021;6:116-22.         45       114       3. Zelyas N, Pabbaraju K, Croxen MA, Lynch T, Buss E, Murphy SA. 2021. Precision response         45       115       to the rise of the SARS-CoV-2 B.1.1.7 variant of concern by combining novel PCR assays         46       114       2021;9:e00315-21.         47       118       2021;9:e00315-21.         48       148       149         49       14	22	103	Agency of Canada.
<ul> <li>100 FileNet Hole decares.</li> <li>107 References:</li> <li>108 1. Ministry of Health, Government of Alberta. Coronavirus, Novel Public Health Disease</li> <li>109 Management Guideline. March 24, 2021. Accessed online May 31, 2021:</li> <li>110 https://open.alberta.ca/publications/coronavirus-covid-19</li> <li>111 2. Pabbaraju K, Wong AA, Douesnard M, Ma R, Gill K, Dieu P, Fonseca K. Development and</li> <li>112 validation of RT-PCR assays for testing for SARS-CoV-2. Official Journal of the Association</li> <li>113 of Medical Microbiology and Infectious Disease Canada 2021;6:116-22.</li> <li>114 3. Zelyas N, Pabbaraju K, Croxen MA, Lynch T, Buss E, Murphy SA. 2021. Precision response</li> <li>115 to the rise of the SARS-CoV-2 B.1.1.7 variant of concern by combining novel PCR assays</li> <li>116 and genome sequencing for rapid variant detection and surveillance. Microbiol Spectr</li> <li>117 2021;9:e00315-21.</li> </ul>		104	Expert Testimony: None declared.
10626107References:371081. Ministry of Health, Government of Alberta. Coronavirus, Novel Public Health Disease38109Management Guideline. March 24, 2021. Accessed online May 31, 2021:36110https://open.alberta.ca/publications/coronavirus-covid-1937110https://open.alberta.ca/publications/coronavirus-covid-19381112.39112validation of RT-PCR assays for testing for SARS-CoV-2. Official Journal of the Association41112validation of RT-PCR assays for testing for SARS-CoV-2. Official Journal of the Association42113of Medical Microbiology and Infectious Disease Canada 2021;6:116-22.431143. Zelyas N, Pabbaraju K, Croxen MA, Lynch T, Buss E, Murphy SA. 2021. Precision response44115to the rise of the SARS-CoV-2 B.1.1.7 variant of concern by combining novel PCR assays51116and genome sequencing for rapid variant detection and surveillance. Microbiol Spectr52118118531185411855118		105	Patents: None declared.
27 28 29107References:1081.Ministry of Health, Government of Alberta. Coronavirus, Novel Public Health Disease33 34109Management Guideline. March 24, 2021. Accessed online May 31, 2021:36 37110https://open.alberta.ca/publications/coronavirus-covid-1938 391112.39 40112validation of RT-PCR assays for testing for SARS-CoV-2. Official Journal of the Association41 41 42113of Medical Microbiology and Infectious Disease Canada 2021;6:116-22.44 451143.45 46115 47to the rise of the SARS-CoV-2 B.1.1.7 variant of concern by combining novel PCR assays55 56 57 58116 40and genome sequencing for rapid variant detection and surveillance. Microbiol Spectr56 57 58118112 40		106	
28 29 30107References:1081.Ministry of Health, Government of Alberta. Coronavirus, Novel Public Health Disease33 34109Management Guideline. March 24, 2021. Accessed online May 31, 2021:36 37110https://open.alberta.ca/publications/coronavirus-covid-1938 39 41112Pabbaraju K, Wong AA, Douesnard M, Ma R, Gill K, Dieu P, Fonseca K. Development and validation of RT-PCR assays for testing for SARS-CoV-2. Official Journal of the Association41 42 43113of Medical Microbiology and Infectious Disease Canada 2021;6:116-22.44 45 471143.Zelyas N, Pabbaraju K, Croxen MA, Lynch T, Buss E, Murphy SA. 2021. Precision response48 49 411115 40to the rise of the SARS-CoV-2 B.1.1.7 variant of concern by combining novel PCR assays and genome sequencing for rapid variant detection and surveillance. Microbiol Spectr51 52 53 54117 4021;9:e00315-21.2021;9:e00315-21.			
29107References:311081. Ministry of Health, Government of Alberta. Coronavirus, Novel Public Health Disease33109Management Guideline. March 24, 2021. Accessed online May 31, 2021:36109https://open.alberta.ca/publications/coronavirus-covid-1937110https://open.alberta.ca/publications/coronavirus-covid-19381112. Pabbaraju K, Wong AA, Douesnard M, Ma R, Gill K, Dieu P, Fonseca K. Development and41112validation of RT-PCR assays for testing for SARS-CoV-2. Official Journal of the Association43113of Medical Microbiology and Infectious Disease Canada 2021;6:116-22.441143. Zelyas N, Pabbaraju K, Croxen MA, Lynch T, Buss E, Murphy SA. 2021. Precision response45115to the rise of the SARS-CoV-2 B.1.1.7 variant of concern by combining novel PCR assays50116and genome sequencing for rapid variant detection and surveillance. Microbiol Spectr521172021;9:e00315-21.541185555118			
31 32 33 341081. Ministry of Health, Government of Alberta. Coronavirus, Novel Public Health Disease Management Guideline. March 24, 2021. Accessed online May 31, 2021: https://open.alberta.ca/publications/coronavirus-covid-1933 34 35 35 36 37110https://open.alberta.ca/publications/coronavirus-covid-1934 35 39 39 4112. Pabbaraju K, Wong AA, Douesnard M, Ma R, Gill K, Dieu P, Fonseca K. Development and validation of RT-PCR assays for testing for SARS-CoV-2. Official Journal of the Association of Medical Microbiology and Infectious Disease Canada 2021;6:116-22.44 45 46 473. Zelyas N, Pabbaraju K, Croxen MA, Lynch T, Buss E, Murphy SA. 2021. Precision response to the rise of the SARS-CoV-2 B.1.1.7 variant of concern by combining novel PCR assays and genome sequencing for rapid variant detection and surveillance. Microbiol Spectr 2021;9:e00315-21.56 57 58118		107	References:
321081. Ministry of Health, Government of Alberta. Coronavirus, Novel Public Health Disease33109Management Guideline. March 24, 2021. Accessed online May 31, 2021:36110https://open.alberta.ca/publications/coronavirus-covid-1937110https://open.alberta.ca/publications/coronavirus-covid-19391112. Pabbaraju K, Wong AA, Douesnard M, Ma R, Gill K, Dieu P, Fonseca K. Development and40validation of RT-PCR assays for testing for SARS-CoV-2. Official Journal of the Association41112validation of RT-PCR assays for testing for SARS-CoV-2. Official Journal of the Association43of Medical Microbiology and Infectious Disease Canada 2021;6:116-22.451143. Zelyas N, Pabbaraju K, Croxen MA, Lynch T, Buss E, Murphy SA. 2021. Precision response48115to the rise of the SARS-CoV-2 B.1.1.7 variant of concern by combining novel PCR assays50116and genome sequencing for rapid variant detection and surveillance. Microbiol Spectr521172021;9:e00315-21.531185454118	30		
<ul> <li>Management Guideline. March 24, 2021. Accessed online May 31, 2021:</li> <li>https://open.alberta.ca/publications/coronavirus-covid-19</li> <li>11 2. Pabbaraju K, Wong AA, Douesnard M, Ma R, Gill K, Dieu P, Fonseca K. Development and</li> <li>validation of RT-PCR assays for testing for SARS-CoV-2. Official Journal of the Association</li> <li>of Medical Microbiology and Infectious Disease Canada 2021;6:116-22.</li> <li>114 3. Zelyas N, Pabbaraju K, Croxen MA, Lynch T, Buss E, Murphy SA. 2021. Precision response</li> <li>to the rise of the SARS-CoV-2 B.1.1.7 variant of concern by combining novel PCR assays</li> <li>and genome sequencing for rapid variant detection and surveillance. Microbiol Spectr</li> <li>117 2021;9:e00315-21.</li> </ul>		100	1 Ministry of Health Covernment of Alberta, Coronavirus, Nevel Public Health Disease
34109Management Guideline. March 24, 2021. Accessed online May 31, 2021:36110https://open.alberta.ca/publications/coronavirus-covid-19371112.381112.391112.41112validation of RT-PCR assays for testing for SARS-CoV-2. Official Journal of the Association41113of Medical Microbiology and Infectious Disease Canada 2021;6:116-22.451143.47115to the rise of the SARS-CoV-2 B.1.1.7 variant of concern by combining novel PCR assays51116and genome sequencing for rapid variant detection and surveillance. Microbiol Spectr531172021;9:e00315-21.54118118551181185611811857118581195911050118511105211153112541175511856118571185811959110501115111152112531135411755118561185711958119591105011151111521125311354114551185611857 <t< td=""><td></td><td>100</td><td>1. Ministry of fleatth, dovernment of Alberta. Coronavirus, Novel Public fleatth Disease</td></t<>		100	1. Ministry of fleatth, dovernment of Alberta. Coronavirus, Novel Public fleatth Disease
<ul> <li>https://open.alberta.ca/publications/coronavirus-covid-19</li> <li>110 https://open.alberta.ca/publications/coronavirus-covid-19</li> <li>111 2. Pabbaraju K, Wong AA, Douesnard M, Ma R, Gill K, Dieu P, Fonseca K. Development and validation of RT-PCR assays for testing for SARS-CoV-2. Official Journal of the Association of Medical Microbiology and Infectious Disease Canada 2021;6:116-22.</li> <li>113 of Medical Microbiology and Infectious Disease Canada 2021;6:116-22.</li> <li>114 3. Zelyas N, Pabbaraju K, Croxen MA, Lynch T, Buss E, Murphy SA. 2021. Precision response to the rise of the SARS-CoV-2 B.1.1.7 variant of concern by combining novel PCR assays and genome sequencing for rapid variant detection and surveillance. Microbiol Spectr 2021;9:e00315-21.</li> <li>118 Jan Management Concern Statement and Stat</li></ul>		100	Management Cuidaling March 24, 2021 Accessed online May 21, 2021
<ul> <li>https://open.alberta.ca/publications/coronavirus-covid-19</li> <li>https://open.alberta.ca/publications/coronavirus-covid-19</li> <li>11</li> <li>Pabbaraju K, Wong AA, Douesnard M, Ma R, Gill K, Dieu P, Fonseca K. Development and validation of RT-PCR assays for testing for SARS-CoV-2. Official Journal of the Association of Medical Microbiology and Infectious Disease Canada 2021;6:116-22.</li> <li>114</li> <li>Zelyas N, Pabbaraju K, Croxen MA, Lynch T, Buss E, Murphy SA. 2021. Precision response to the rise of the SARS-CoV-2 B.1.1.7 variant of concern by combining novel PCR assays and genome sequencing for rapid variant detection and surveillance. Microbiol Spectr 2021;9:e00315-21.</li> </ul>		109	Management Guideline. March 24, 2021. Accessed Online May 31, 2021.
<ul> <li>2. Pabbaraju K, Wong AA, Douesnard M, Ma R, Gill K, Dieu P, Fonseca K. Development and validation of RT-PCR assays for testing for SARS-CoV-2. Official Journal of the Association of Medical Microbiology and Infectious Disease Canada 2021;6:116-22.</li> <li>3. Zelyas N, Pabbaraju K, Croxen MA, Lynch T, Buss E, Murphy SA. 2021. Precision response to the rise of the SARS-CoV-2 B.1.1.7 variant of concern by combining novel PCR assays and genome sequencing for rapid variant detection and surveillance. Microbiol Spectr 2021;9:e00315-21.</li> <li>118</li> </ul>			
<ul> <li>111 2. Pabbaraju K, Wong AA, Douesnard M, Ma R, Gill K, Dieu P, Fonseca K. Development and validation of RT-PCR assays for testing for SARS-CoV-2. Official Journal of the Association of Medical Microbiology and Infectious Disease Canada 2021;6:116-22.</li> <li>114 3. Zelyas N, Pabbaraju K, Croxen MA, Lynch T, Buss E, Murphy SA. 2021. Precision response to the rise of the SARS-CoV-2 B.1.1.7 variant of concern by combining novel PCR assays and genome sequencing for rapid variant detection and surveillance. Microbiol Spectr 2021;9:e00315-21.</li> <li>118</li> </ul>	37	110	https://open.alberta.ca/publications/coronavirus-covid-19
<ul> <li>validation of RT-PCR assays for testing for SARS-CoV-2. Official Journal of the Association</li> <li>of Medical Microbiology and Infectious Disease Canada 2021;6:116-22.</li> <li>Zelyas N, Pabbaraju K, Croxen MA, Lynch T, Buss E, Murphy SA. 2021. Precision response</li> <li>to the rise of the SARS-CoV-2 B.1.1.7 variant of concern by combining novel PCR assays</li> <li>and genome sequencing for rapid variant detection and surveillance. Microbiol Spectr</li> <li>2021;9:e00315-21.</li> </ul>			
<ul> <li>validation of RT-PCR assays for testing for SARS-CoV-2. Official Journal of the Association</li> <li>of Medical Microbiology and Infectious Disease Canada 2021;6:116-22.</li> <li>Intersection of the SARS-CoV-2 B.1.1.7 variant of concern by combining novel PCR assays</li> <li>and genome sequencing for rapid variant detection and surveillance. Microbiol Spectr</li> <li>2021;9:e00315-21.</li> </ul>		111	2. Pabbaraju K, Wong AA, Douesnard M, Ma R, Gill K, Dieu P, Fonseca K. Development and
<ul> <li>Validation of RT-PCR assays for testing for SARS-CoV-2. Official Journal of the Association</li> <li>of Medical Microbiology and Infectious Disease Canada 2021;6:116-22.</li> <li>3. Zelyas N, Pabbaraju K, Croxen MA, Lynch T, Buss E, Murphy SA. 2021. Precision response</li> <li>to the rise of the SARS-CoV-2 B.1.1.7 variant of concern by combining novel PCR assays</li> <li>and genome sequencing for rapid variant detection and surveillance. Microbiol Spectr</li> <li>2021;9:e00315-21.</li> </ul>			
<ul> <li>of Medical Microbiology and Infectious Disease Canada 2021;6:116-22.</li> <li>114</li> <li>3. Zelyas N, Pabbaraju K, Croxen MA, Lynch T, Buss E, Murphy SA. 2021. Precision response</li> <li>to the rise of the SARS-CoV-2 B.1.1.7 variant of concern by combining novel PCR assays</li> <li>and genome sequencing for rapid variant detection and surveillance. Microbiol Spectr</li> <li>2021;9:e00315-21.</li> </ul>		112	validation of RT-PCR assays for testing for SARS-CoV-2. Official Journal of the Association
<ul> <li>44 113 of Medical Microbiology and Infectious Disease Canada 2021;6:116-22.</li> <li>45</li> <li>46 114</li> <li>47 114</li> <li>48 2elyas N, Pabbaraju K, Croxen MA, Lynch T, Buss E, Murphy SA. 2021. Precision response</li> <li>48 to the rise of the SARS-CoV-2 B.1.1.7 variant of concern by combining novel PCR assays</li> <li>50 and genome sequencing for rapid variant detection and surveillance. Microbiol Spectr</li> <li>53 117 2021;9:e00315-21.</li> <li>54 117 2021;9:e00315-21.</li> </ul>			
<ul> <li>46 47</li> <li>414</li> <li>3. Zelyas N, Pabbaraju K, Croxen MA, Lynch T, Buss E, Murphy SA. 2021. Precision response 48 49</li> <li>49</li> <li>115</li> <li>40</li> <li>51</li> <li>52</li> <li>53</li> <li>54</li> <li>55</li> <li>56</li> <li>56</li> <li>57</li> <li>58</li> <li>59</li> </ul>		113	of Medical Microbiology and Infectious Disease Canada 2021;6:116-22.
<ul> <li>47</li> <li>48</li> <li>49</li> <li>415</li> <li>50</li> <li>51</li> <li>51</li> <li>51</li> <li>52</li> <li>53</li> <li>54</li> <li>55</li> <li>56</li> <li>56</li> <li>57</li> <li>58</li> <li>59</li> </ul>	45		
<ul> <li>to the rise of the SARS-CoV-2 B.1.1.7 variant of concern by combining novel PCR assays</li> <li>to the rise of the SARS-CoV-2 B.1.1.7 variant of concern by combining novel PCR assays</li> <li>and genome sequencing for rapid variant detection and surveillance. Microbiol Spectr</li> <li>2021;9:e00315-21.</li> </ul>		114	3. Zelyas N, Pabbaraju K, Croxen MA, Lynch T, Buss E, Murphy SA. 2021. Precision response
49115to the rise of the SARS-CoV-2 B.1.1.7 variant of concern by combining novel PCR assays5051116and genome sequencing for rapid variant detection and surveillance. Microbiol Spectr53531172021;9:e00315-21.55561185758595950			
50and genome sequencing for rapid variant detection and surveillance. Microbiol Spectr521172021;9:e00315-21.55118555611857585950		115	to the rise of the SARS-CoV-2 B.1.1.7 variant of concern by combining novel PCR assays
51116and genome sequencing for rapid variant detection and surveillance. Microbiol Spectr531172021;9:e00315-21.55118555611855595050		110	
52     53       53     54       54     117       55       56       57       58       59		116	and genome sequencing for ranid variant detection and surveillance. Microbiol Spectr
54       117       2021;9:e00315-21.         55       56       118         57       58       59		110	and genome sequencing for rapid variant detection and surveinance. Will oblor speech
55 56 118 57 58 59		117	2021-0-0021E 21
56 118 57 58 59		11/	2021,3.000313-21.
57 58 59		440	
58 59		118	
59			۲ ۲
60 https://mc.manuscriptcentral.com/clinchem			
	60		https://mc.manuscriptcentral.com/clinchem

**Table 1**. SARS-CoV-2 PCR results from paired residual point of care testing ID NOW positive

swabs (rSwab-PCR) and nasopharyngeal swabs.

			Nasopharyng	geal Swab					
			Positive	Negative					
		Positive	101	1					
	rSwa	Negative	10	1					
21 22 23	Table 2. \	/ariant of Concer	n PCR results	from paired	d residua	al point	of care	e testing ID N	١OW
24	positive s	wabs (rSwab) an	d nasopharyn	geal swabs.					
			1		N	asopha	ryngeal	Swab	1
		SARS-CoV-2 PC	R						
		Result			Posit			Negative	
			VoC Resu		γ	WT	Unr	N/A	Tota
			α	64	1	0	1	1	67
	rSwab		WT			10			10
	150005	Positive	Unresolve						8
			Pres. Pos		1				1
			Lab error		2	3			15
		Negative	N/A	7		1	2	1	11
		Indeterminate		1					1
			Total	89	4	15	3	2	113
25	Whole ge	nome sequencin	g identificatio	n of the gai	mma (γ)	VoC (P	1 linea	ge) was only	
26 27	-	d on nasopharyn 01Y target only p	-	-		-			